AstraZeneca announced that its SERENA-4 Phase III trial of Etcamah (camizestrant) combined with palbociclib failed to meet the primary endpoint of statistically significant improvement in progression-free survival for upfront 1st-line advanced ER-positive breast cancer, although a numerical improvement was observed. The global trial enrolled 1,371 adult patients newly diagnosed with Stage IV de novo or recurrent disease who had not received prior systemic treatment for metastatic disease. AstraZeneca stated the outcome sharpens focus on maximizing patient benefit based on SERENA-6 results and reinforces the importance of ESR1 testing. The company remains confident in the long-term potential of Etcamah as it advances broader programs including CAMBRIA-1 and CAMBRIA-2 trials involving approximately 10,000 patients. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals.

AstraZeneca reported positive high-level results from the planned interim analysis of the DeLLphi-305 Phase III trial, demonstrating that Imfinzi (durvalumab) plus Amgen's Imdelltra (tarlatamab) significantly improved overall survival and progression-free survival versus Imfinzi alone as first-line maintenance treatment for extensive-stage small cell lung cancer. The trial randomized 563 patients who had not progressed following induction therapy, establishing the combination as a new standard of care with no new safety signals identified. These findings reinforce Imfinzi's role in reshaping lung cancer treatment and will be shared with global regulatory authorities. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals.

The US FDA approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer upon detection of an emergent ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy. This accelerated approval is based on the SERENA-6 Phase III trial results, which demonstrated a 56% reduction in the risk of disease progression or death (HR: 0.44) compared to standard-of-care treatment. The filing also notes that the FDA concurrently approved a companion diagnostic test for detecting ESR1 mutations via circulating tumor DNA. AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines in oncology, rare disease, and bio-pharmaceuticals.